Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Seeking Alpha
Jeffrey S. Farrow - CFO & Chief Strategy Officer David Nakasone - Head of Investor Relations Conference Call Participants Jenna Davidner - Barclays Bank PLC, Research Division Presentation Jenna Davidner Barclays Bank PLC, Research Division All right. I think we're ready to get started. Good afternoon, everyone. Welcome to the Barclays Miami Healthcare Conference. I'm Jenna Davidner. I'm one of the analysts here on the specialty pharmaceuticals team and very pleased to have Tarsus Pharmaceuticals on the stage with me this afternoon. From the company, we have Jeff Farrow, the CFO; and Dave Nakasone, who is the Head of Investor Relations. Thank you both for taking the time. Jeffrey S. Farrow CFO & Chief Strategy Officer Well, thank you, Jenna. It's great to be here. Question-and-Answer Session Jenna Davidner Barclays Bank PLC, Research Division So just to level set the conversation, the company is a couple of years into the launch of XDEMVY. So maybe for peo
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals (TARS) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance [Yahoo! Finance]Yahoo! Finance
- Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals (TARS) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TARS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- Tarsus Pharmaceuticals (TARS) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
TARS
Earnings
- 2/23/26 - Miss
TARS
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- TARS's page on the SEC website